Dacarbazine

Alkylating Drug — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Key facts

Dacarbazine is an ofp drug in the Alkylating Drug class catalogued in DrugCentral. It was first approved by the FDA in 1975. Its mechanism of action is classified as Alkylating Activity. DrugCentral lists 2 molecular targets, including MMP9 and POLA2. Recorded indications include Hodgkin's disease and Metastatic malignant melanoma.

• Approval status: ofp (first approved 1975 by the FDA).
• Drug class: Alkylating Drug.
• Mechanism of action: Alkylating Activity.
• Molecular targets: MMP9 and POLA2 (2 listed in DrugCentral).
• Indications: Hodgkin's disease and Metastatic malignant melanoma.
• ATC code: L01AX04 (Other alkylating agents).
• Molecular formula: C6H10N6O; molecular weight 182.19 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

• Hodgkin's disease
• Metastatic malignant melanoma

Off-label uses (1)

• Pancreatic Neuroendocrine Tumor

Contraindications (10)

• Anemia
• Bone marrow depression
• Breastfeeding (mother)
• Disease of liver
• Hepatic necrosis
• Hepatic vein thrombosis
• Kidney disease
• Leukopenia
• Pregnancy, function
• Thrombocytopenic disorder

Mechanism & targets

• Mechanism of action (MoA): Alkylating Activity
• Established pharmacologic class: Alkylating Drug

Molecular targets (2)

Target	Gene	Action	Activity
Matrix metalloproteinase-9	MMP9	unknown	IC50 6.25
DNA polymerase alpha subunit B	POLA2	unknown	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1975-05-27	FDA	—	BAYER HLTHCARE

ATC classification

ATC code	Therapeutic hierarchy
L01AX04	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › ALKYLATING AGENTS › Other alkylating agents

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Febrile neutropenia	1003.5
Pulmonary toxicity	544.7
Neutropenia	527.8
Second primary malignancy	478.7
Acute myeloid leukaemia	383.8
Disease progression	306.6
Neuropathy peripheral	297.5
Cardiotoxicity	220.9
Malignant neoplasm progression	189.7
Myelodysplastic syndrome	158.6
Pneumocystis jirovecii pneumonia	137.2
Pneumonitis	136.8

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Dacarbazine is on its molecule page.

• Molecular formula: C₆H₁₀N₆O
• Molecular weight: 182.19 g/mol
• CAS number: 4342-03-4
• InChIKey: FDKXTQMXEQVLRF-ZHACJKMWSA-N
• PubChem CID: 135398738

CN(C)\N=N\C1=C(NC=N1)C(N)=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Dacarbazine used for?

DrugCentral lists the following indications for Dacarbazine: Hodgkin's disease and Metastatic malignant melanoma.

How does Dacarbazine work?

Dacarbazine is classified as Alkylating Activity; its molecular targets in DrugCentral include MMP9 and POLA2.

When was Dacarbazine first approved?

Dacarbazine was first approved by the FDA in 1975.

What drug class does Dacarbazine belong to?

Dacarbazine is in the Alkylating Drug class.

What is the chemical formula of Dacarbazine?

Dacarbazine has the molecular formula C6H10N6O and a molecular weight of 182.19 g/mol.

Sources

• DrugCentral drug card 773 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL476 — compound record and bioactivity
• PubChem CID 135398738 — chemical identifiers
• DrugBank DB00851 — drug record
• FDA UNII 7GR28W0FJI — substance identity
• DailyMed: FDA labels for Dacarbazine — current prescribing information (label search)
• UniProt P14780 (MMP9) — target protein
• UniProt Q14181 (POLA2) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.